Literature DB >> 23192869

Pandemic 2009 H1N1 influenza A virus carrying a Q136K mutation in the neuraminidase gene is resistant to zanamivir but exhibits reduced fitness in the guinea pig transmission model.

Michael M Kaminski1, Annette Ohnemus, Peter Staeheli, Dennis Rubbenstroth.   

Abstract

Resistance of influenza A viruses to neuraminidase inhibitors can arise through mutations in the neuraminidase (NA) gene. We show here that a Q136K mutation in the NA of the 2009 pandemic H1N1 virus confers a high degree of resistance to zanamivir. Resistance is accompanied by reduced numbers of NA molecules in viral particles and reduced intrinsic enzymatic activity of mutant NA. Interestingly, the Q136K mutation strongly impairs viral fitness in the guinea pig transmission model.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23192869      PMCID: PMC3554154          DOI: 10.1128/JVI.02507-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor.

Authors:  J N Varghese; J L McKimm-Breschkin; J B Caldwell; A A Kortt; P M Colman
Journal:  Proteins       Date:  1992-11

2.  Global transmission of oseltamivir-resistant influenza.

Authors:  Anne Moscona
Journal:  N Engl J Med       Date:  2009-03-02       Impact factor: 91.245

3.  Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility.

Authors:  Hui-Ling Yen; Louise M Herlocher; Erich Hoffmann; Mikhail N Matrosovich; Arnold S Monto; Robert G Webster; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

4.  Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers.

Authors:  L M Cass; C Efthymiopoulos; A Bye
Journal:  Clin Pharmacokinet       Date:  1999       Impact factor: 6.447

5.  Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en.

Authors:  L V Gubareva; M J Robinson; R C Bethell; R G Webster
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

6.  Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network.

Authors:  N T Wetherall; T Trivedi; J Zeller; C Hodges-Savola; J L McKimm-Breschkin; M Zambon; F G Hayden
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

7.  Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors.

Authors:  Mikhail Matrosovich; Tatyana Matrosovich; Jackie Carr; Noel A Roberts; Hans-Dieter Klenk
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States.

Authors:  Nila J Dharan; Larisa V Gubareva; John J Meyer; Margaret Okomo-Adhiambo; Reginald C McClinton; Steven A Marshall; Kirsten St George; Scott Epperson; Lynnette Brammer; Alexander I Klimov; Joseph S Bresee; Alicia M Fry
Journal:  JAMA       Date:  2009-03-02       Impact factor: 56.272

9.  Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo.

Authors:  J Carr; J Ives; L Kelly; R Lambkin; J Oxford; D Mendel; L Tai; N Roberts
Journal:  Antiviral Res       Date:  2002-05       Impact factor: 5.970

10.  Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08.

Authors:  Siri H Hauge; Susanne Dudman; Katrine Borgen; Angie Lackenby; Olav Hungnes
Journal:  Emerg Infect Dis       Date:  2009-02       Impact factor: 6.883

View more
  14 in total

1.  Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir.

Authors:  Mélanie Samson; Yacine Abed; François-Marc Desrochers; Stephanie Hamilton; Angela Luttick; Simon P Tucker; Melinda J Pryor; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

2.  An Amino Acid in the Stalk Domain of N1 Neuraminidase Is Critical for Enzymatic Activity.

Authors:  Mark Zanin; Susu Duan; Sook-San Wong; Gyanendra Kumar; Pradyumna Baviskar; Emily Collin; Charles Russell; Subrata Barman; Benjamin Hause; Richard Webby
Journal:  J Virol       Date:  2017-01-03       Impact factor: 5.103

3.  The avian-origin PB1 gene segment facilitated replication and transmissibility of the H3N2/1968 pandemic influenza virus.

Authors:  Isabel Wendel; Dennis Rubbenstroth; Jennifer Doedt; Georg Kochs; Jochen Wilhelm; Peter Staeheli; Hans-Dieter Klenk; Mikhail Matrosovich
Journal:  J Virol       Date:  2015-01-28       Impact factor: 5.103

4.  Evaluation of recombinant 2009 pandemic influenza A (H1N1) viruses harboring zanamivir resistance mutations in mice and ferrets.

Authors:  Andrés Pizzorno; Yacine Abed; Chantal Rhéaume; Xavier Bouhy; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

5.  Molecular mechanism of the airborne transmissibility of H9N2 avian influenza A viruses in chickens.

Authors:  Lei Zhong; Xiaoquan Wang; Qunhui Li; Dong Liu; Hongzhi Chen; Mingjun Zhao; Xiaobing Gu; Liang He; Xiaowen Liu; Min Gu; Daxin Peng; Xiufan Liu
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

6.  In Vitro and In Vivo Characterization of Novel Neuraminidase Substitutions in Influenza A(H1N1)pdm09 Virus Identified Using Laninamivir-Mediated In Vitro Selection.

Authors:  Khristine Kaith S Lloren; Jin Jung Kwon; Won-Suk Choi; Ju Hwan Jeong; Su Jeong Ahn; Young Ki Choi; Yun Hee Baek; Min-Suk Song
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

7.  Metadata-driven comparative analysis tool for sequences (meta-CATS): an automated process for identifying significant sequence variations that correlate with virus attributes.

Authors:  B E Pickett; M Liu; E L Sadat; R B Squires; J M Noronha; S He; W Jen; S Zaremba; Z Gu; L Zhou; C N Larsen; I Bosch; L Gehrke; M McGee; E B Klem; R H Scheuermann
Journal:  Virology       Date:  2013-09-14       Impact factor: 3.616

8.  The M segment of the 2009 pandemic influenza virus confers increased neuraminidase activity, filamentous morphology, and efficient contact transmissibility to A/Puerto Rico/8/1934-based reassortant viruses.

Authors:  Patricia J Campbell; Shamika Danzy; Constantinos S Kyriakis; Martin J Deymier; Anice C Lowen; John Steel
Journal:  J Virol       Date:  2014-01-15       Impact factor: 5.103

9.  Multiple influenza A (H3N2) mutations conferring resistance to neuraminidase inhibitors in a bone marrow transplant recipient.

Authors:  Alireza Eshaghi; Sarah Shalhoub; Paul Rosenfeld; Aimin Li; Rachel R Higgins; Peter J Stogios; Alexei Savchenko; Nathalie Bastien; Yan Li; Coleman Rotstein; Jonathan B Gubbay
Journal:  Antimicrob Agents Chemother       Date:  2014-09-22       Impact factor: 5.191

10.  Novel H7N9 influenza virus shows low infectious dose, high growth rate, and efficient contact transmission in the guinea pig model.

Authors:  Jon D Gabbard; Daniel Dlugolenski; Debby Van Riel; Nicolle Marshall; Summer E Galloway; Elizabeth W Howerth; Patricia J Campbell; Cheryl Jones; Scott Johnson; Lauren Byrd-Leotis; David A Steinhauer; Thijs Kuiken; S Mark Tompkins; Ralph Tripp; Anice C Lowen; John Steel
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.